MOUNJARO 7 5MG KWIKPEN
Manufactured By LILLY PRODUCTS
Composition TIRZEPATIDE 7 5MG
RS 18562.50
MRP RS 20625.00
(10% OFF)
Includes all taxes
Package SIZE
( 2.4ML )
100% Authentic
Products
Free
Shipping*
Products
Return Policy
Description:
Mounjaro 7.5mg KwikPen
Mounjaro 7.5mg KwikPen (Tirzepatide 7.5mg) is a third-step dose escalation pen in the Mounjaro (Tirzepatide) treatment journey — a first-in-class dual Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly and Company, delivered via a single-dose prefilled auto-injector KwikPen. Tirzepatide is indicated as an adjunct to diet and exercise to improve glycaemic control in adults and children aged 10 years and older with Type 2 Diabetes Mellitus (T2DM), and for weight management in adults with obesity or overweight with weight-related comorbidities. The 7.5mg dose is the third step in the mandatory 4-weekly escalation protocol (2.5mg → 5mg → 7.5mg), typically used from weeks 9–12 of therapy, bridging patients toward the 10mg maintenance dose. Available from Shabbir Medical Hall at the best price in India, this genuine Eli Lilly prescription KwikPen is available online with fast cold-chain delivery nationwide.
BENEFITS: At 7.5mg, Tirzepatide begins to deliver clinically meaningful HbA1c reduction (approximately –1.6 to –1.8%) and significant body weight loss (approximately –7 to –8 kg) — matching or exceeding the maximum effect of GLP-1 only agonists like semaglutide 1mg. The 7.5mg dose represents a critical threshold where both the GIP and GLP-1 pathways are sufficiently engaged to drive substantial appetite suppression, reduced caloric intake, improved postprandial glucose control, and meaningful weight reduction. Patients often begin to notice measurable weight loss and improved blood sugar readings at this dose level.
USAGE OVERVIEW: Mounjaro 7.5mg KwikPen is administered as a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm — on the same day each week. It follows 4 weeks at 5mg and precedes 4 weeks at 10mg (or remains the maintenance dose if sufficient glycaemic and weight goals are achieved at 7.5mg). The KwikPen is a single-use, prefilled, disposable auto-injector requiring no assembly.
SAFETY OVERVIEW: GI side effects (nausea, diarrhoea, vomiting) are the most common, typically improved compared to earlier dose steps. A boxed warning applies for thyroid C-cell tumour risk. Contraindicated in MTC/MEN 2 history. Cold-chain storage at 2–8°C is mandatory. Prescription and specialist supervision required.
Uses / Indications:
ROLE OF THE 7.5MG DOSE IN TIRZEPATIDE THERAPY:
Mounjaro 7.5mg KwikPen is the third step in the mandatory dose escalation schedule for all Tirzepatide patients. It is prescribed for use during weeks 9–12 of therapy (following 4 weeks at 2.5mg and 4 weeks at 5mg). Its specific purpose is to allow gradual physiological adaptation to incrementally higher GIP/GLP-1 receptor engagement, minimising gastrointestinal side effects while progressively increasing therapeutic benefit. Some patients with T2DM and/or obesity may achieve their HbA1c and weight loss targets at 7.5mg and remain at this maintenance dose without further escalation, as directed by their diabetologist or endocrinologist.
PRIMARY USES:
• Type 2 Diabetes Mellitus (T2DM): Adjunct to diet and exercise to improve glycaemic control (HbA1c reduction) in adults and children aged 10 years and older. Used as monotherapy or add-on to metformin, SGLT-2 inhibitors, sulphonylureas, or basal insulin. At 7.5mg, patients begin to see clinically meaningful HbA1c reduction (–1.6 to –1.8%) comparable to the best available GLP-1 receptor agonists
• Weight Management (as Zepbound / same molecule): In adults with BMI ≥30 kg/m² (obesity) or BMI ≥27 kg/m² with weight-related comorbidities (hypertension, dyslipidaemia, T2DM, CVD, obstructive sleep apnea). At 7.5mg, clinically significant weight loss (~7–8 kg from baseline) begins to be established, with continued loss expected at higher maintenance doses
• Cardiovascular Risk Reduction: Tirzepatide's cardioprotective incretin effects are active across all dose levels including 7.5mg
• Obstructive Sleep Apnea (OSA): Benefits established at maintenance doses (10mg, 12.5mg, 15mg); the 7.5mg is an intermediate step toward therapeutic maintenance dose
ADDITIONAL USES:
• Non-Alcoholic Fatty Liver Disease / Steatohepatitis (NAFLD/NASH): Significant liver fat reduction demonstrated from 5mg and above
• Polycystic Ovary Syndrome (PCOS): Weight and metabolic improvement
• Heart Failure with Preserved Ejection Fraction (HFpEF) + Obesity (SUMMIT trial data)
Mounjaro 7.5mg KwikPen is the third step in the mandatory dose escalation schedule for all Tirzepatide patients. It is prescribed for use during weeks 9–12 of therapy (following 4 weeks at 2.5mg and 4 weeks at 5mg). Its specific purpose is to allow gradual physiological adaptation to incrementally higher GIP/GLP-1 receptor engagement, minimising gastrointestinal side effects while progressively increasing therapeutic benefit. Some patients with T2DM and/or obesity may achieve their HbA1c and weight loss targets at 7.5mg and remain at this maintenance dose without further escalation, as directed by their diabetologist or endocrinologist.
PRIMARY USES:
• Type 2 Diabetes Mellitus (T2DM): Adjunct to diet and exercise to improve glycaemic control (HbA1c reduction) in adults and children aged 10 years and older. Used as monotherapy or add-on to metformin, SGLT-2 inhibitors, sulphonylureas, or basal insulin. At 7.5mg, patients begin to see clinically meaningful HbA1c reduction (–1.6 to –1.8%) comparable to the best available GLP-1 receptor agonists
• Weight Management (as Zepbound / same molecule): In adults with BMI ≥30 kg/m² (obesity) or BMI ≥27 kg/m² with weight-related comorbidities (hypertension, dyslipidaemia, T2DM, CVD, obstructive sleep apnea). At 7.5mg, clinically significant weight loss (~7–8 kg from baseline) begins to be established, with continued loss expected at higher maintenance doses
• Cardiovascular Risk Reduction: Tirzepatide's cardioprotective incretin effects are active across all dose levels including 7.5mg
• Obstructive Sleep Apnea (OSA): Benefits established at maintenance doses (10mg, 12.5mg, 15mg); the 7.5mg is an intermediate step toward therapeutic maintenance dose
ADDITIONAL USES:
• Non-Alcoholic Fatty Liver Disease / Steatohepatitis (NAFLD/NASH): Significant liver fat reduction demonstrated from 5mg and above
• Polycystic Ovary Syndrome (PCOS): Weight and metabolic improvement
• Heart Failure with Preserved Ejection Fraction (HFpEF) + Obesity (SUMMIT trial data)
Interactions / Warnings:
BOXED WARNING — THYROID CARCINOMA (APPLIES AT ALL TIRZEPATIDE DOSES INCLUDING 7.5MG):
Tirzepatide is CONTRAINDICATED in patients with personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Screen all patients for personal and family thyroid history before initiating any Tirzepatide dose. Patients should be counselled to self-examine their neck regularly and report any new neck lump, hoarseness, voice change, difficulty swallowing, or persistent neck pain to their physician. Routine serum calcitonin screening or thyroid ultrasound is not universally recommended for asymptomatic patients — discuss with your endocrinologist if individual thyroid risk factors are present.
PANCREATITIS PRECAUTION:
Discontinue Tirzepatide permanently if acute pancreatitis is confirmed — do NOT rechallenge. Use with caution (or avoid) in patients with: history of pancreatitis, gallstones, alcoholism, or markedly elevated triglycerides (>500 mg/dL). Monitor triglyceride levels — Tirzepatide reduces triglycerides in most patients; however, if levels are already very high at baseline, the pancreatic risk must be weighed carefully.
PERIOPERATIVE / SURGERY / ANAESTHESIA — CRITICAL HOLD INSTRUCTION:
Tirzepatide significantly slows gastric emptying. This increases the risk of pulmonary aspiration of gastric contents under general anaesthesia or sedation — a potentially life-threatening complication. Inform your surgeon and anaesthesiologist before ANY planned or emergency procedure that you are receiving Mounjaro 7.5mg weekly. Most anaesthesia society guidelines recommend holding once-weekly GIP/GLP-1 agonists (including Tirzepatide) for at least 1 week before any elective surgery or procedure requiring general anaesthesia or conscious sedation. Resume Tirzepatide only after your physician confirms it is safe to do so post-procedure and you are tolerating oral intake normally.
DIABETIC RETINOPATHY — MONITOR DURING ESCALATION:
Rapid improvement in glycaemic control (as seen during Tirzepatide escalation) can be associated with transient worsening of pre-existing diabetic retinopathy — a well-established phenomenon with any rapid HbA1c reduction. Ensure ophthalmological (dilated fundus) examination at baseline if T2DM patients have not had one recently; plan a follow-up eye examination within 6 months of achieving target HbA1c.
DRIVING & MACHINE OPERATION:
Tirzepatide itself does not impair alertness or cognition; however, hypoglycaemia (when combined with insulin or sulphonylureas) can impair driving ability. If hypoglycaemic episodes have occurred, do NOT drive until blood glucose has normalised (≥5.0 mmol/L / 90 mg/dL) and symptoms have fully resolved.
DEHYDRATION PRECAUTION:
The combination of osmotic fluid shift (Tirzepatide GI effects) and reduced oral intake (appetite suppression) can cause dehydration, particularly in hot climates (relevant for India) or during vigorous exercise. Drink at least 2–2.5 litres of water per day during Tirzepatide therapy; increase intake during high-heat days, illness, or exercise. Patients on concurrent diuretics (furosemide, hydrochlorothiazide) or SGLT-2 inhibitors are at heightened dehydration risk — monitor blood pressure and renal function.
Pregnancy interaction:
• Mounjaro 7.5mg (Tirzepatide) is NOT recommended during pregnancy and must be discontinued at least 2 months before a planned pregnancy — Tirzepatide's mean half-life of approximately 5 days (with full systemic clearance requiring several weeks) necessitates early discontinuation
• Animal reproductive toxicology studies at doses above the maximum recommended human dose showed embryo-foetal toxicity and teratogenic effects. The potential risk to human foetuses cannot be excluded
• Women with T2DM using Tirzepatide who become pregnant should immediately switch to insulin (the established standard of care for glycaemic management during pregnancy) — contact your diabetologist or endocrinologist urgently
• As Tirzepatide promotes weight loss, its use for weight management must be discontinued at the start of pregnancy — weight loss is not a recommended therapeutic goal during pregnancy
• Tirzepatide does not protect against sexually transmitted infections. Use appropriate contraception throughout therapy
BREASTFEEDING:
• Tirzepatide's presence in human breast milk is unknown. Animal studies demonstrated excretion of Tirzepatide and adverse renal development effects in suckling animals. Due to the potential for serious adverse reactions in nursing infants, Mounjaro is NOT recommended during breastfeeding. Discuss the risk-benefit balance of continuing breastfeeding versus continuing Tirzepatide with your treating physician
CONTRACEPTION — CRITICAL INTERACTION WITH ORAL CONTRACEPTIVE PILLS:
• Tirzepatide significantly slows gastric emptying, which can reduce the absorption rate and peak plasma concentration of oral contraceptive pills (OCPs) — potentially reducing their efficacy
• Use a non-oral or additional method of contraception (condom, IUD, contraceptive implant, or injectable contraceptive) for at least 4 weeks after each Tirzepatide dose escalation step and for 4 weeks after stopping therapy
• At the 7.5mg escalation step (weeks 9–12), women on OCPs should ensure they are using additional contraceptive cover throughout this 4-week period
• Inform your gynaecologist and diabetologist that you are escalating Tirzepatide doses if you rely on oral contraception
Expert advice:
1. THE 7.5MG DOSE IS A CLINICAL MILESTONE — TRACK YOUR RESULTS:
• By week 9 of Tirzepatide therapy (when the 7.5mg pen begins), most patients have started to notice meaningful weight loss and improved blood sugar readings
• This is the point at which your diabetologist will usually review your Week 4 and Week 8 HbA1c and body weight data to determine whether to continue escalation to 10mg or maintain 7.5mg as your ongoing dose
• Keep a detailed record of your fasting morning blood glucose, post-meal glucose (2 hours after eating), body weight (weekly, same conditions — morning, before food), and any side effects
• Bring this log to your week 12 review appointment — it is critical for the escalation or maintenance decision
2. GI SIDE EFFECTS AT 7.5MG SHOULD BE IMPROVING — IF NOT, TELL YOUR DOCTOR:
• Patients who have successfully completed 2.5mg and 5mg steps have built up GI tolerability
• If nausea, vomiting, or diarrhoea at 7.5mg is as severe as during the initial 2.5mg step, or is getting worse rather than better, this is not expected and must be reported to your diabetologist
• Options include: extending the 7.5mg dose period by an additional 4 weeks before escalating, reducing the dose back to 5mg temporarily, or reviewing co-medications that may be contributing
• Do NOT simply stop Mounjaro without medical guidance — abrupt discontinuation causes rapid reversal of glycaemic and weight benefits
3. REVIEW SULPHONYLUREA AND INSULIN DOSES BEFORE WEEK 9 — HYPOGLYCAEMIA RISK INCREASES:
• If you are taking a sulphonylurea (Glimepiride, Glibenclamide) or insulin alongside Tirzepatide and your diabetologist has not yet reduced these doses, the 7.5mg step increases hypoglycaemia risk significantly
• Contact your diabetologist before or at the start of the 7.5mg step to review and reduce these medications proactively
• Keep glucose tablets or sugar sachets accessible at all times
• Know the signs of hypoglycaemia (shakiness, sweating, palpitations, confusion) and how to treat (15g fast-acting glucose, wait 15 minutes, retest)
4. MAINTAIN COLD CHAIN DISCIPLINE — EVEN ONE WARM PEN IS A WASTED DOSE:
• At Rs 18,562.50 per pen, correct cold-chain storage is financially and therapeutically critical
• Never store Mounjaro 7.5mg in the car, at room temperature for more than 21 days, or in a warm environment
• If you travel domestically or internationally, use a validated medication travel cooler (e.g., 4AllFamily, FRIO wallet, or medical-grade insulin travel cooler) to maintain 2–8°C during transit
• If a pen has been accidentally frozen or stored above 30°C — discard it and contact Shabbir Medical Hall for a replacement. A degraded pen delivers no therapeutic effect despite normal appearance
5. USE ORAL CONTRACEPTIVES? — TAKE ACTION AT EVERY DOSE ESCALATION:
• Each time you move to a new Tirzepatide dose step (including the switch to 7.5mg), the degree of gastric emptying slowing incrementally increases — further reducing OCP absorption reliability
• Ensure you are using an additional non-oral contraceptive method (condom, IUD, contraceptive implant, or injectable) for the full 4 weeks of the 7.5mg step
• Discuss long-term contraceptive planning with your gynaecologist — an intrauterine device (IUD), subdermal implant, or injectable contraceptive may be a more reliable option for the duration of Tirzepatide therapy
MONITORING SCHEDULE AT WEEKS 9–12 (7.5MG DOSE STEP):
• Fasting Blood Glucose: Daily morning monitoring (home glucometer); target as directed by diabetologist (typically 80–130 mg/dL / 4.4–7.2 mmol/L for most T2DM patients)
• Post-Prandial Glucose (2 hours after meals): 2–3 times per week; target <180 mg/dL / <10 mmol/L
• HbA1c: Blood test at end of week 12 (or as scheduled by diabetologist) — key decision point for dose maintenance or escalation
• Body Weight: Weekly, same time of day, same conditions — track cumulative weight loss from Tirzepatide initiation
• Blood Pressure: Fortnightly — Tirzepatide lowers BP; review antihypertensive doses if BP falling below 100/60 mmHg
• Renal Function (Creatinine, eGFR): At week 12 review (or sooner if GI side effects have caused dehydration)
• Lipid Profile: At week 12 or as directed — Tirzepatide significantly reduces triglycerides and increases HDL
• Liver Function Tests (ALT, AST): If NAFLD/fatty liver is a concurrent indication — assess hepatic fat response at 3 months
• Eye Examination (Fundoscopy): If not done at baseline or if known diabetic retinopathy — schedule during this dose period
COMPLIANCE AND LIFESTYLE TIPS:
• Injection day reminder: Set a recurring weekly calendar alarm labelled 'Mounjaro 7.5mg — same day, same time'
• If GI side effects remain bothersome at 7.5mg: eat a light low-fat snack (crackers, yoghurt, plain rice) at least 30 minutes before injecting on injection day; avoid high-fat, spicy, or very sugary meals on injection day and the following day
• Walking 20–30 minutes after meals reduces post-prandial glucose more efficiently at this dose level — Tirzepatide and mild post-meal activity are highly synergistic for blood sugar control
• Keep a nutrition diary during weeks 9–12 — reduced appetite at 7.5mg can inadvertently lead to protein deficiency; target 1.0–1.2g protein per kg body weight daily to preserve muscle mass during weight loss
• Stay connected to your diabetes care team — many patients feel the greatest confidence and compliance improvement during the 7.5mg step because results become tangible; use this momentum
Side Effects:
Most patients who have successfully tolerated 2.5mg and 5mg for 4 weeks each will find that GI side effects at 7.5mg are manageable and improving. The 7.5mg dose may still trigger a transient mild increase in nausea and/or diarrhoea during the first 1–2 weeks of this step — this is expected and typically resolves by week 2–3 at this dose level.
COMMON SIDE EFFECTS (>1 in 10 — primarily GI, dose-dependent, transient):
• Nausea: Most common; typically mild to moderate at 7.5mg and better tolerated than at earlier escalation steps for most patients; eat small, low-fat, low-sugar meals; avoid large or spicy meals on injection day and the day after
• Diarrhoea: Loose stools, urgency; usually brief at this dose step; maintain hydration; contact doctor if prolonged (>2 days) or associated with signs of dehydration
• Vomiting: Less common than at 2.5mg or 5mg escalation steps; if persistent contact doctor
• Constipation: Increased at higher doses due to further slowing of gastric emptying; increase dietary fibre and fluid intake
• Decreased Appetite: A primary therapeutic benefit; ensure adequate nutritional intake even with reduced hunger signals — do not skip meals entirely
• Abdominal Discomfort / Bloating / Heartburn: Mild, transient; related to slowed gastric motility
• Injection Site Reactions: Pain, redness, itching, or minor swelling; rotate injection sites weekly
• Fatigue: Some patients report tiredness during initial dose escalation — typically resolves within 1–2 weeks at a new dose level
SERIOUS SIDE EFFECTS (contact your doctor or emergency services immediately):
BOXED WARNING — THYROID C-CELL TUMOURS:
• Tirzepatide caused thyroid C-cell tumours (including medullary thyroid carcinoma / MTC) in rodent studies at clinically relevant doses. Relevance in humans is not yet established, but the class Boxed Warning applies to all GIP/GLP-1 receptor agonists including Tirzepatide at all doses
• CONTRAINDICATED in patients with personal OR family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia Type 2 (MEN 2)
• Report any neck lump, swelling, hoarseness, difficulty swallowing, or persistent neck pain to your doctor immediately
PANCREATITIS (rare but life-threatening):
• Acute pancreatitis reported with GLP-1 receptor agonists across all doses
• Signs: Severe, persistent abdominal pain — especially radiating to the back — with nausea and vomiting that feels different from typical GI side effects
• Action: STOP Mounjaro 7.5mg immediately and seek emergency medical care — do NOT wait; do NOT assume it is a GI side effect
• Tirzepatide has not been studied in patients with a prior history of pancreatitis — avoid in this population
HYPOGLYCAEMIA (primarily in combination with sulphonylureas or insulin):
• Tirzepatide 7.5mg alone rarely causes hypoglycaemia (glucose-dependent insulin secretion mechanism)
• Increased risk when combined with sulphonylureas (glimepiride, glibenclamide) or insulin — dose reduction of these agents is typically required when Tirzepatide is initiated (usually done by week 5–8 of therapy)
• By week 9 (7.5mg), if hypoglycaemia episodes have not been addressed by sulphonylurea/insulin dose reduction, contact your diabetologist immediately for further dose review
• Symptoms: shakiness, sweating, palpitations, dizziness, confusion — treat with 15g fast-acting glucose (glucose tablets, 3 teaspoons of sugar in water, or fruit juice)
HYPERSENSITIVITY REACTIONS (rare):
• Anaphylaxis, angioedema, severe urticaria — seek emergency care immediately if facial swelling, throat tightening, difficulty breathing, or widespread rash occurs after injection
ACUTE KIDNEY INJURY (AKI):
• Secondary to dehydration from severe GI side effects; ensure adequate fluid intake (minimum 2–2.5 litres per day); seek medical care if urine output decreases significantly
GALLBLADDER DISEASE:
• Rapid weight loss on Tirzepatide increases gallstone and cholecystitis risk; report upper right abdominal pain, jaundice, or fever
EMERGENCY SIGNS — SEEK IMMEDIATE MEDICAL HELP:
• Severe persistent abdominal pain radiating to the back (possible pancreatitis)
• Neck lump, hoarseness, or difficulty swallowing (possible thyroid tumour)
• Facial swelling, difficulty breathing (anaphylaxis)
• Chest pain, fainting, or very rapid or very slow heartbeat
How to use:
Tirzepatide requires a strict step-up dosing protocol. Mounjaro 7.5mg KwikPen is the THIRD STEP — used during weeks 9–12 of therapy. Skipping this step risks significantly worse GI side effects and reduced tolerability.
COMPLETE MANDATORY DOSE ESCALATION SCHEDULE:
• Weeks 1–4: 2.5 mg SC once weekly (Mounjaro 2.5mg KwikPen — starting dose for tolerability)
• Weeks 5–8: 5.0 mg SC once weekly (Mounjaro 5mg KwikPen — first therapeutic step)
• Weeks 9–12: 7.5 mg SC once weekly ← MOUNJARO 7.5MG KWIKPEN (THIS PRODUCT)
• Weeks 13–16: 10.0 mg SC once weekly (Mounjaro 10mg KwikPen — if further control needed)
• Weeks 17–20: 12.5 mg SC once weekly (Mounjaro 12.5mg KwikPen — if further escalation needed)
• Weeks 21+: 15.0 mg SC once weekly (Mounjaro 15mg KwikPen — maximum dose)
STAYING AT 7.5MG AS MAINTENANCE DOSE:
• If HbA1c and body weight goals are achieved at 7.5mg, your diabetologist may decide to maintain this dose long-term without further escalation
• Clinical decision to escalate beyond 7.5mg is based on: HbA1c at week 12, body weight trajectory, tolerability of 7.5mg dose, and individual treatment goals
• Do NOT self-escalate to 10mg without explicit physician instruction
ROUTE AND INJECTION TECHNIQUE:
• Subcutaneous (SC) injection ONLY — into abdomen (≥2 inches from navel), upper thigh (anterior/lateral), or outer upper arm
• Rotate injection sites every week, both within and between body areas
• Do NOT inject into muscle (IM) or vein (IV)
• Do NOT inject at the same site as concurrent insulin injection — use a different injection area
HOW TO USE THE MOUNJARO 7.5MG KWIKPEN:
• Step 1 — Warm up: Remove pen from refrigerator 30 minutes before use — room temperature injection is more comfortable and ensures smooth pen mechanism function
• Step 2 — Inspect: Check solution through pen window — should be clear, colourless to slightly yellow; do NOT use if cloudy, discoloured, or particulate matter present
• Step 3 — Prepare site: Select and clean injection site with alcohol swab; let dry completely before injecting (do not blow or rub)
• Step 4 — Inject: Remove pen cap; press pen firmly and flat against skin until you hear the first click (injection starts); hold firmly for at least 10 seconds until you hear the second click (injection complete) and orange needle cover has locked into place
• Step 5 — Dispose: Place entire used pen in a puncture-resistant sharps disposal container immediately after use — do NOT recap or reuse the pen
INJECTION DAY FLEXIBILITY / MISSED DOSE:
• Inject on the SAME DAY each week; time of day is flexible (morning is preferred to minimise nocturia from GI side effects)
• If a dose is missed: administer as soon as remembered IF within 4 days (96 hours) of the scheduled day; if more than 4 days have passed, skip that week's dose and resume on the next regularly scheduled day
• NEVER take two doses in the same week to compensate for a missed dose
STORAGE — MANDATORY COLD CHAIN:
• Refrigerate at 2–8°C at all times — do NOT freeze; do NOT place next to cooling element inside the refrigerator
• Once removed from refrigerator: may be kept at room temperature (≤30°C) for up to 21 days maximum
• Store in original carton; protect from light, heat, and moisture
• Do NOT shake the pen — Tirzepatide solution should not be agitated
• Keep out of reach of children; discard after the expiry date printed on the pen label
How it works:
Mounjaro 7.5mg contains Tirzepatide — a synthetic 39 amino acid linear peptide based on the native GIP peptide sequence, incorporating a C20 fatty diacid moiety for albumin binding, enabling once-weekly dosing (plasma half-life ~5 days / 116.7 hours). At 7.5mg, both the GIP and GLP-1 receptor pathways are substantially engaged — delivering a clinical effect that begins to clearly surpass that of GLP-1-only receptor agonists.
GIP RECEPTOR AGONISM (Glucose-Dependent Insulinotropic Polypeptide):
• GIP is an incretin hormone secreted by K-cells in the duodenum and proximal jejunum in response to carbohydrate and fat ingestion
• Tirzepatide binds GIP receptors on pancreatic beta cells → glucose-dependent insulin secretion (only when blood glucose is elevated → minimal standalone hypoglycaemia risk)
• Hypothalamic GIP receptor activation → reduced appetite, decreased food intake, altered food preferences (reduced hedonic eating)
• Adipose tissue GIP receptors → improved lipid metabolism, reduction in visceral and subcutaneous fat depots
• Enhanced glucagon suppression during postprandial hyperglycaemia, reducing glucose production from the liver
GLP-1 RECEPTOR AGONISM (Glucagon-Like Peptide-1):
• GLP-1 is secreted by L-cells in the distal small intestine and colon in response to nutrient intake
• Tirzepatide binds GLP-1 receptors on pancreatic beta cells → glucose-dependent insulin secretion + suppression of inappropriate glucagon secretion
• Gastric smooth muscle GLP-1 receptors → slowed gastric emptying → prolonged satiety, blunted postprandial glucose spike, reduced portion sizes
• Hypothalamus and brainstem GLP-1 receptors → powerful central appetite suppression and reduced caloric intake
• Cardiac and vascular GLP-1 receptors → blood pressure reduction, cardioprotective benefits
WHY THE 7.5MG DOSE IS CLINICALLY SIGNIFICANT:
• At 7.5mg, both GIP and GLP-1 pathway engagement reaches the threshold of robust clinical effect
• In the SURPASS-1 through SURPASS-5 trials, Tirzepatide 5mg demonstrated meaningful efficacy; 7.5mg and above demonstrated superior results
• HbA1c reduction at 7.5mg: approximately –1.6% to –1.9% from baseline (matching or exceeding maximum semaglutide 1mg effect of –1.86%)
• Body weight loss at 7.5mg: approximately –7 to –8.5 kg from baseline — substantially more than any available GLP-1 agonist at equivalent tolerability-optimised doses
• The dual pathway synergy at 7.5mg explains why many patients with moderate T2DM and moderate obesity achieve their clinical targets without needing dose escalation to 10mg or beyond
Faq for medicine:
Mounjaro 7.5mg KwikPen (Tirzepatide 7.5mg) is the third dose escalation step in Tirzepatide therapy (weeks 9–12), used for Type 2 Diabetes blood sugar control and significant weight loss in adults and children aged 10+. It is the first dose where many patients achieve clinically meaningful HbA1c and weight results.
2. How does Mounjaro 7.5mg Tirzepatide Injection work?
Tirzepatide 7.5mg activates both GIP and GLP-1 receptors simultaneously — triggering glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and powerfully suppressing appetite centrally. At 7.5mg, dual receptor engagement reaches a threshold that surpasses the maximum effect of GLP-1 agonists like semaglutide.
3. When do I use the Mounjaro 7.5mg KwikPen in my dose schedule?
Mounjaro 7.5mg KwikPen is used during weeks 9–12 of Tirzepatide therapy — after 4 weeks each at 2.5mg and 5mg. Inject once weekly on the same day each week, subcutaneously into the abdomen, thigh, or upper arm. Your diabetologist may keep you at 7.5mg long-term if treatment targets are met.
4. What are the side effects of Mounjaro 7.5mg Tirzepatide Injection?
Most common: nausea, diarrhoea, constipation — typically milder than at earlier escalation steps. Serious risks: BOXED WARNING for thyroid C-cell tumours (contraindicated in MTC/MEN 2 history); pancreatitis; hypoglycaemia when combined with insulin or sulphonylureas. Inform surgeon/anaesthesiologist before any planned procedure.
5. Can I buy Mounjaro 7.5mg KwikPen online at the best price in India?
Yes. Buy Mounjaro 7.5mg KwikPen (Tirzepatide 7.5mg) online from Shabbir Medical Hall at 10% OFF MRP (Rs 18,562.50 vs Rs 20,625.00 per KwikPen). Genuine Eli Lilly product. Valid prescription required. Temperature-controlled cold-chain delivery across Hyderabad, Bangalore, Mumbai, Delhi, and Chennai.
Medicine interaction:
INSULIN AND SULPHONYLUREAS — HYPOGLYCAEMIA RISK (MOST CLINICALLY IMPORTANT):
• Combining Tirzepatide 7.5mg with sulphonylureas (Glimepiride, Glibenclamide, Glipizide) or insulin carries a significant hypoglycaemia risk
• Your diabetologist should have already reduced sulphonylurea or basal insulin doses when Tirzepatide was initiated (typically at the 2.5mg or 5mg step); if not yet done, this is critical to address before or at the 7.5mg step
• Target pre-meal fasting glucose and post-meal glucose to guide insulin/sulphonylurea adjustment; monitor blood glucose 2–3x daily during the first 2 weeks at 7.5mg
ORAL MEDICATIONS — GASTRIC EMPTYING INTERACTION (IMPORTANT AT ALL DOSES):
• Tirzepatide substantially slows gastric emptying — this delays the absorption (Tmax) of all oral medications taken with food or around mealtimes
• ORAL CONTRACEPTIVE PILLS (OCPs): Reduced absorption → reduced efficacy → use additional non-oral contraception for ≥4 weeks after each dose escalation step (see Pregnancy & Breastfeeding section)
• LEVOTHYROXINE (Thyroid hormone replacement): Must be taken on an empty stomach 30–60 minutes before breakfast on Mounjaro injection days and every other day; monitor TSH every 8–12 weeks during dose escalation
• WARFARIN / OTHER ORAL ANTICOAGULANTS (e.g., Acenocoumarol): Delayed absorption alters INR stability — monitor INR more frequently during dose escalation; adjust warfarin dose under anticoagulation clinic guidance
• TIME-CRITICAL ORAL MEDICATIONS (seizure medications, cardiac medications such as digoxin): Take at least 1 hour before or 4+ hours after meals on injection days to minimise absorption delay
METFORMIN:
• Safe and commonly co-prescribed with Tirzepatide in T2DM; no clinically meaningful pharmacokinetic interaction; continue at same dose; ensure adequate hydration if GI side effects from both agents overlap
SGLT-2 INHIBITORS (Empagliflozin/Empaworth, Dapagliflozin/Forxiga):
• Safe evidence-based combination for T2DM + CKD or CVD; complementary mechanisms; additive volume depletion (from SGLT-2 osmotic diuresis + Tirzepatide GI fluid loss) — ensure adequate hydration and monitor blood pressure
DPP-4 INHIBITORS (Sitagliptin, Linagliptin, Teneligliptin):
• Should NOT be combined with Tirzepatide — both work on incretin pathways (GLP-1); no additional therapeutic benefit; combination is not recommended by prescribing guidelines
SUPPLEMENT INTERACTIONS:
• Herbal weight loss supplements (Garcinia Cambogia, Green Tea Extract, Synephrine/Bitter Orange): Do not combine with Tirzepatide without physician guidance — unpredictable GI and cardiovascular effects
• Chromium Picolinate, Berberine: Additive blood glucose-lowering effect with sulphonylureas/insulin → increased hypoglycaemia risk when all three are combined; disclose all supplements to your diabetologist
• Fibre supplements (Psyllium husk / Isabgol): May help manage constipation from Tirzepatide — safe to use; take at a different time from oral medications (fibre can also delay medication absorption)
